Emicizumab is a humanized, specific monoclonal antibody that binds to factors IX and X, mediating factor X activation thereby bypassing the normal mechanism of FVIII-mediated activation that is missing in patients with hemophilia A [94, 95]. This evidence concerns the gene F10 and hemophilia A.